• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase I ALS trial shows positive results for stem cell therapy

Phase I ALS trial shows positive results for stem cell therapy

May 4, 2015
CenterWatch Staff

Hanyang University and Corestem, both in Seoul, South Korea, and Inje University College of Medicine in Busan released positive results in a phase I clinical trial for amyotrophic lateral sclerosis (ALS).

ALS is a rapidly progressive, invariably fatal neurological disease that attacks the motor nerve cells (neurons) responsible for controlling voluntary muscles. The Hanyang University team’s phase I trial had two goals: to test whether stem cells were a safe treatment for ALS, and to learn whether two injections of the cells might prove more beneficial than a single injection.

“In our pilot study we followed a group of ALS patients for six months after giving them a single injection of mesenchymal stromal cells (MSCs) and found the treatment to be both safe and feasible,” said the trial’s co-leader, Seung Hyun Kim, Ph.D., director of Hanyang University Hospital’s Cell Therapy Center and professor in Hanyang University’s department of neurology. “In this next phase, we wanted to see if two injections would prove even more beneficial, and we wanted to follow the participants for a longer period of time to determine if the treatment proved safe for a longer term than in the pilot phase.”

MSCs, which are found in bone marrow, generate bone, cartilage and fat cells that support the formation of blood and fibrous connective tissue. They have emerged as a potentially promising treatment for ALS due to their ability to regenerate lost or damaged cells and for their anti-inflammatory capabilities.

Eight patients with definite or probable ALS were enrolled in the new study, although one died shortly after enrollment. After a three-month lead-in period, MSCs were isolated from each patient’s bone marrow two times, at an interval of 26 days, with each group of MSCs then expanded in the lab for 28 days before being injected into the donor patients. The seven patients received intrathecal (cerebrospinal fluid space) injections of their own MSCs in two separate treatments given 26 days apart.

Kim said, “Intrathecal injections have the advantages of not only avoiding invasive surgical technique that had been done in the previous other group’s study, but also it’s easy to do repeated procedures without harm to the patients.”

Their ALS functional status and safety was then evaluated for 12 months after the first injection.

“No serious adverse events were observed during this period,” said co-leader Ki-Wook Oh, M.D., also of Hanyang University’s neurology department. “Additionally, there was no advancement in ALS symptoms in any of the patients during the 12-month period.”

Kim said, “This study shows that stem cells as a therapeutic approach for ALS are feasible and well-tolerated at least for 12 months, supporting the need for a late-stage clinical trial to examine their in-depth safety, biological effects and efficacy. Randomized, semi-doubleblind, controlled phase II clinical data on 72 ALS patients, which recently was submitted to the Korean FDA, will be released in the near future.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing